Clinical Trial Update: A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating iparomlimab and tuvonralimab with SOX chemotherapy as first-line treatment for unresectable HER2-negative gastric or gastroeso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Gastric Cancer (Diagnosis), Gastric Cancer (GC) | Phase 4 | Status: NOT_YET_RECRUITING